The Quell Device
The Quell wearable pain relief device from NeuroMetrix fights chronic pain by stimulating nerves in the upper calf, which send neural pulses to the brain. This causes the brain to release natural opiates that block pain signals and deliver widespread pain relief throughout the body.
Quell is a new alternative to treating chronic pain, and the first device of its kind approved by the FDA for use during sleep.
The Quell Relief App
Atomic developed the accompanying Quell Relief mobile app, which lets the user:
- Start and stop therapy sessions and adjust the intensity of therapy.
- Customize therapy (including stimulation patterns and sleep modes) to suit their pain level.
- Track and review detailed insights about therapy, sleep, pain, and activity.
It also displays the battery level and the remaining life of the device’s electrodes, and it links directly to Quell’s online store.
Quell Relief syncs with the device via Bluetooth LE. Both iOS and Android versions are available.
Atomic designed the system architecture and wrote software and firmware for:
Shai Gozani, M.D., Ph.D., CEO, NeuroMetrix, Inc.
The team’s careful project management, client communication, cutting-edge architecture, and cohesive design strategy helped the team ship the product on time and on budget.
Reflecting back on the multi-year, high-profile project, Robinson said Atomic helped his company arrive at a special moment in time.
“We'd never done anything this big. Ever,” he said. “We’re live across all the major pillars Atomic said they would deliver on. It was delivered on time, on budget, to expectation, live. Not three or four milestones late with people leaving and the platform half-baked and full of bugs.”
StoryLoom began open-beta in December 2022. A global launch is scheduled for the spring of 2023.
“Our future is pretty bright,” said Robinson. “We’ve been given a rare opportunity to find success by chasing opportunities Starship Enterprise-style: going where people aren’t—pushing boundaries.”